ClinicalTrials.gg
Not yet recruitingNCT07769424Updated Oct 7, 2026

PACE Cognition Proof-of-Concept Study

An interventional study of Physiologic Pacemaker Programming and Standard Pacemaker Programming in Symptomatic Bradycardia, Cognitive Function and Pacemaker, sponsored by University of Minnesota. Not yet recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by University of Minnesota · Not applicable, Interventional, and Treatment

Updated Oct 7, 2026Start date movedGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This proof-of-concept study will evaluate whether physiologic pacemaker programming improves cognitive function and health status in patients with symptomatic bradycardia who require permanent pacemaker implantation.

Participants will be randomized to either standard pacemaker programming at 60 beats per minute or individualized physiologic rate pacing between 60 and 90 beats per minute using the myPACE algorithm. Cognitive function and health status will be assessed before pacemaker implantation and again at the routine 3-month pacemaker clinic visit.

The primary outcome is change in Montreal Cognitive Assessment total score. The secondary outcome is change in SF-36 mental component summary score.

Read the detailed description

Cardiac pacing may improve cognition by restoring physiologic heart rates, enhancing cerebral perfusion, and improving overall cardiovascular function in patients with symptomatic bradycardia who require permanent pacemaker implantation. In current clinical practice, the lower pacing rate is commonly programmed to 60 beats per minute, which is below the normal resting heart rate in many adults.

PACE Cognition is a proof-of-concept study evaluating the impact of physiologic pacemaker programming on cognitive function and health status. Patients requiring permanent pacemaker implantation for bradycardia will be screened before device implantation. Interested and eligible patients will provide written informed consent before any study-specific procedures are performed.

Baseline cognitive and health-status assessments will be completed before pacemaker implantation. Cognitive function will be assessed using the Montreal Cognitive Assessment, a brief standardized screening instrument that evaluates multiple cognitive domains, including memory, attention, language, visuospatial ability, executive function, and orientation. Health status and functional well-being will be assessed using the SF-36 questionnaire, including the mental component summary score.

Participants will be randomized to either standard pacing at 60 beats per minute or individualized physiologic rate pacing between 60 and 90 beats per minute using the myPACE algorithm. Follow-up Montreal Cognitive Assessment and SF-36 assessments will be repeated at the routine 3-month pacemaker clinic visit to evaluate changes in cognitive performance and health status between the pacing strategies.

02

Conditions studied

  • Symptomatic Bradycardia
  • Cognitive Function
  • Pacemaker
  • Health Status

Browse trials for

Keywords

  • PACE Cognition
  • Symptomatic bradycardia
  • Physiologic pacing
  • Pacemaker programming
  • myPACE algorithm
03

In context

Bradycardia

317 studies on the registry are indexed under Bradycardia; 71 are open to participants now.

This study's planned enrollment of 110 is close to the median of 100 across 187 interventional studies indexed under Bradycardia.

Browse Bradycardia studies →

Lead sponsor

University of Minnesota is the lead sponsor of 1,216 studies on the registry; 197 are open to participants now.

Of its 136 completed or terminated interventional studies of FDA-regulated products, 95 (70%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Patient requiring a pacemaker for bradycardia

Exclusion criteria

Exclusion Criteria:

  • Vulnerable adult unable to give consent
  • Unable to answer questionnaire
  • Children
  • Pregnant women/persons
  • Prisoners
  • Adults lacking capacity to consent or adults with diminished or fluctuating capacity to consent
  • Non-English speakers
  • Individuals unable to read
  • Employees or students of the researcher
  • Active members of the military or DoD personnel
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
110 participants (estimated)

Study arms

  • Active comparator
    Standard Pacemaker Programming

    Participants randomized to this arm will receive standard pacemaker programming with a lower pacing rate of 60 beats per minute after permanent pacemaker implantation for bradycardia.

    Device: Standard Pacemaker Programming

  • Experimental
    Physiologic Pacemaker Programming

    Participants randomized to this arm will receive individualized physiologic pacemaker programming between 60 and 90 beats per minute using the myPACE algorithm after permanent pacemaker implantation for bradycardia.

    Device: Physiologic Pacemaker Programming

Interventions

  • DevicePhysiologic Pacemaker Programming

    Individualized physiologic pacemaker programming between 60 and 90 beats per minute will be performed using the myPACE algorithm.

    Also known as: myPACE Algorithm

  • DeviceStandard Pacemaker Programming

    Standard pacemaker programming with a lower pacing rate of 60 beats per minute will be used after permanent pacemaker implantation.

06

What researchers measure

Primary outcomes

  1. Change in Montreal Cognitive Assessment Total Score

    Change in Montreal Cognitive Assessment total score from baseline to 3 months after pacemaker implantation will be compared between participants randomized to standard pacemaker programming at 60 beats per minute and participants randomized to physiologic pacemaker programming between 60 and 90 beats per minute using the myPACE algorithm. The Montreal Cognitive Assessment is scored from 0 to 30, with higher scores indicating better cognitive function.

    Time frame: Baseline to 3 months after pacemaker implantation

Secondary outcomes

  1. Change in Short Form 36 Health Survey Mental Component Summary Score

    Change in Short Form 36 Health Survey Mental Component Summary score from baseline to 3 months after pacemaker implantation will be compared between participants randomized to standard pacemaker programming at 60 beats per minute and participants randomized to physiologic pacemaker programming between 60 and 90 beats per minute using the myPACE algorithm. The Short Form 36 Health Survey Mental Component Summary score ranges from 0 to 100, with higher scores indicating better mental health and psychological well-being.

    Time frame: Baseline to 3 months after pacemaker implantation

07

Study locations

2 sites
08

Updates

1 registry update since Sep 25, 2026
Start date
Oct 1, 2026→Dec 1, 2026
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Start date Oct 1, 2026→Dec 1, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07769424
Collaborators
Medtronic
Responsible party
Sponsor
First posted
Aug 18, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Oct 1, 2028 (estimated)
Completion
Oct 1, 2028 (estimated)
Last update
Oct 7, 2026

Study contacts

Markus Meyer, MD
Contact
markusmeyermd@gmail.com
802-922-0656
Samantha Wansing
Contact
hoppx054@umn.edu
Selma Carlson, MD
principal investigator · University of Minnesota
Markus Meyer, MD
principal investigator · University of Minnesota

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion